Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
暂无分享，去创建一个
Akshay S. Desai | P. Ponikowski | S. Solomon | A. Desai | J. McMurray | M. Sabatine | P. Jhund | L. Køber | B. Claggett | D. Lindholm | S. Inzucchi | M. Kosiborod | F. Martinez | P. Dewan | A. Langkilde | O. Bengtsson | M. Sjostrand
[1] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[2] Akshay S. Desai,et al. A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) , 2019, European journal of heart failure.
[3] Adrian F Hernandez,et al. Heart failure drug treatment , 2019, The Lancet.
[4] Declare–Timi Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .
[5] J. McMurray,et al. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.
[6] K. Mahaffey,et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.
[7] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[8] S. Solomon,et al. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. , 2014, JACC. Heart failure.
[9] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.